nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—ABCB1—peripheral nervous system neoplasm	0.147	1	CbGaD
Nilotinib—ABCG2—Topotecan—peripheral nervous system neoplasm	0.044	0.118	CbGbCtD
Nilotinib—UGT1A1—Etoposide—peripheral nervous system neoplasm	0.0313	0.0841	CbGbCtD
Nilotinib—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0305	0.082	CbGbCtD
Nilotinib—CYP2B6—Tretinoin—peripheral nervous system neoplasm	0.0288	0.0773	CbGbCtD
Nilotinib—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0218	0.0586	CbGbCtD
Nilotinib—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0188	0.0505	CbGbCtD
Nilotinib—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0175	0.0471	CbGbCtD
Nilotinib—ABCG2—Etoposide—peripheral nervous system neoplasm	0.0172	0.0463	CbGbCtD
Nilotinib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0159	0.0427	CbGbCtD
Nilotinib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0159	0.0427	CbGbCtD
Nilotinib—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0152	0.0409	CbGbCtD
Nilotinib—CYP2B6—Cisplatin—peripheral nervous system neoplasm	0.0123	0.0331	CbGbCtD
Nilotinib—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.0117	0.0316	CbGbCtD
Nilotinib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.011	0.0296	CbGbCtD
Nilotinib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0095	0.0256	CbGbCtD
Nilotinib—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.00917	0.0246	CbGbCtD
Nilotinib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00883	0.0238	CbGbCtD
Nilotinib—CYP2B6—Doxorubicin—peripheral nervous system neoplasm	0.00825	0.0222	CbGbCtD
Nilotinib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00677	0.0182	CbGbCtD
Nilotinib—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.00651	0.0175	CbGbCtD
Nilotinib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00631	0.017	CbGbCtD
Nilotinib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0062	0.0167	CbGbCtD
Nilotinib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00423	0.0114	CbGbCtD
Nilotinib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00406	0.0109	CbGbCtD
Nilotinib—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00399	0.0107	CbGbCtD
Nilotinib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00372	0.01	CbGbCtD
Nilotinib—EPHB2—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.00329	0.738	CbGdCrCtD
Nilotinib—Imatinib—NTRK1—peripheral nervous system neoplasm	0.00327	0.731	CrCbGaD
Nilotinib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00254	0.00682	CbGbCtD
Nilotinib—EPHB3—nerve—peripheral nervous system neoplasm	0.00233	0.0495	CbGeAlD
Nilotinib—EPHA4—nerve—peripheral nervous system neoplasm	0.00194	0.0414	CbGeAlD
Nilotinib—EPHA4—ganglion—peripheral nervous system neoplasm	0.00192	0.0409	CbGeAlD
Nilotinib—EPHA4—tongue—peripheral nervous system neoplasm	0.0019	0.0404	CbGeAlD
Nilotinib—EPHB2—brainstem—peripheral nervous system neoplasm	0.00152	0.0323	CbGeAlD
Nilotinib—CDC42BPB—trigeminal ganglion—peripheral nervous system neoplasm	0.00151	0.0322	CbGeAlD
Nilotinib—MAPK8—brainstem—peripheral nervous system neoplasm	0.00121	0.0258	CbGeAlD
Nilotinib—EPHB3—trigeminal ganglion—peripheral nervous system neoplasm	0.00113	0.024	CbGeAlD
Nilotinib—CA1—nerve—peripheral nervous system neoplasm	0.00108	0.0229	CbGeAlD
Nilotinib—HCK—trigeminal ganglion—peripheral nervous system neoplasm	0.00104	0.0221	CbGeAlD
Nilotinib—EPHB3—brainstem—peripheral nervous system neoplasm	0.000999	0.0213	CbGeAlD
Nilotinib—CA6—parotid gland—peripheral nervous system neoplasm	0.000928	0.0197	CbGeAlD
Nilotinib—CA3—parotid gland—peripheral nervous system neoplasm	0.000878	0.0187	CbGeAlD
Nilotinib—LCK—trigeminal ganglion—peripheral nervous system neoplasm	0.000866	0.0184	CbGeAlD
Nilotinib—CA4—nerve—peripheral nervous system neoplasm	0.000842	0.0179	CbGeAlD
Nilotinib—EPHA4—brainstem—peripheral nervous system neoplasm	0.000834	0.0178	CbGeAlD
Nilotinib—CA4—ganglion—peripheral nervous system neoplasm	0.000831	0.0177	CbGeAlD
Nilotinib—EPHB4—trigeminal ganglion—peripheral nervous system neoplasm	0.000824	0.0175	CbGeAlD
Nilotinib—EPHA2—trigeminal ganglion—peripheral nervous system neoplasm	0.000808	0.0172	CbGeAlD
Nilotinib—TEK—trigeminal ganglion—peripheral nervous system neoplasm	0.000789	0.0168	CbGeAlD
Nilotinib—EPHB4—parotid gland—peripheral nervous system neoplasm	0.000777	0.0165	CbGeAlD
Nilotinib—MAPK14—brainstem—peripheral nervous system neoplasm	0.000769	0.0164	CbGeAlD
Nilotinib—EPHA2—parotid gland—peripheral nervous system neoplasm	0.000763	0.0162	CbGeAlD
Nilotinib—EPHB6—trigeminal ganglion—peripheral nervous system neoplasm	0.000754	0.016	CbGeAlD
Nilotinib—Ponatinib—ABCB1—peripheral nervous system neoplasm	0.000745	0.166	CrCbGaD
Nilotinib—EPHA8—cerebellum—peripheral nervous system neoplasm	0.000716	0.0152	CbGeAlD
Nilotinib—EPHB6—parotid gland—peripheral nervous system neoplasm	0.000711	0.0151	CbGeAlD
Nilotinib—MAPK11—cerebellum—peripheral nervous system neoplasm	0.000666	0.0142	CbGeAlD
Nilotinib—CDC42BPB—cerebellum—peripheral nervous system neoplasm	0.00066	0.0141	CbGeAlD
Nilotinib—MAP2K5—trigeminal ganglion—peripheral nervous system neoplasm	0.000645	0.0137	CbGeAlD
Nilotinib—CSF1R—trigeminal ganglion—peripheral nervous system neoplasm	0.000629	0.0134	CbGeAlD
Nilotinib—MAP2K5—parotid gland—peripheral nervous system neoplasm	0.000608	0.0129	CbGeAlD
Nilotinib—MAPK8—cerebellum—peripheral nervous system neoplasm	0.000597	0.0127	CbGeAlD
Nilotinib—KIT—trigeminal ganglion—peripheral nervous system neoplasm	0.000571	0.0122	CbGeAlD
Nilotinib—MAP2K5—brainstem—peripheral nervous system neoplasm	0.00057	0.0121	CbGeAlD
Nilotinib—PDGFRB—trigeminal ganglion—peripheral nervous system neoplasm	0.000558	0.0119	CbGeAlD
Nilotinib—KIT—parotid gland—peripheral nervous system neoplasm	0.000539	0.0115	CbGeAlD
Nilotinib—PDGFRB—parotid gland—peripheral nervous system neoplasm	0.000526	0.0112	CbGeAlD
Nilotinib—TIE1—cerebellum—peripheral nervous system neoplasm	0.000518	0.011	CbGeAlD
Nilotinib—KIT—brainstem—peripheral nervous system neoplasm	0.000506	0.0108	CbGeAlD
Nilotinib—ABL1—trigeminal ganglion—peripheral nervous system neoplasm	0.000497	0.0106	CbGeAlD
Nilotinib—BRAF—cerebellum—peripheral nervous system neoplasm	0.000496	0.0106	CbGeAlD
Nilotinib—EPHB3—cerebellum—peripheral nervous system neoplasm	0.000493	0.0105	CbGeAlD
Nilotinib—ABL1—parotid gland—peripheral nervous system neoplasm	0.000469	0.00998	CbGeAlD
Nilotinib—Imatinib—ABCB1—peripheral nervous system neoplasm	0.000458	0.102	CrCbGaD
Nilotinib—ABL2—cerebellum—peripheral nervous system neoplasm	0.00045	0.00957	CbGeAlD
Nilotinib—CA7—cerebellum—peripheral nervous system neoplasm	0.000443	0.00943	CbGeAlD
Nilotinib—ABL1—brainstem—peripheral nervous system neoplasm	0.00044	0.00937	CbGeAlD
Nilotinib—EPHA4—cerebellum—peripheral nervous system neoplasm	0.000411	0.00876	CbGeAlD
Nilotinib—CA9—cerebellum—peripheral nervous system neoplasm	0.000389	0.00828	CbGeAlD
Nilotinib—CA4—parotid gland—peripheral nervous system neoplasm	0.000385	0.0082	CbGeAlD
Nilotinib—MAPK14—cerebellum—peripheral nervous system neoplasm	0.000379	0.00807	CbGeAlD
Nilotinib—CA14—cerebellum—peripheral nervous system neoplasm	0.000369	0.00785	CbGeAlD
Nilotinib—CA4—brainstem—peripheral nervous system neoplasm	0.000361	0.00769	CbGeAlD
Nilotinib—EPHB4—cerebellum—peripheral nervous system neoplasm	0.00036	0.00765	CbGeAlD
Nilotinib—TEK—cerebellum—peripheral nervous system neoplasm	0.000344	0.00732	CbGeAlD
Nilotinib—CA2—trigeminal ganglion—peripheral nervous system neoplasm	0.000339	0.00721	CbGeAlD
Nilotinib—EPHB6—cerebellum—peripheral nervous system neoplasm	0.000329	0.007	CbGeAlD
Nilotinib—CA2—parotid gland—peripheral nervous system neoplasm	0.000319	0.0068	CbGeAlD
Nilotinib—ABCG2—trigeminal ganglion—peripheral nervous system neoplasm	0.000314	0.00667	CbGeAlD
Nilotinib—PDGFRA—cerebellum—peripheral nervous system neoplasm	0.000312	0.00664	CbGeAlD
Nilotinib—CA2—brainstem—peripheral nervous system neoplasm	0.0003	0.00638	CbGeAlD
Nilotinib—ABCG2—parotid gland—peripheral nervous system neoplasm	0.000296	0.0063	CbGeAlD
Nilotinib—MAP2K5—cerebellum—peripheral nervous system neoplasm	0.000281	0.00599	CbGeAlD
Nilotinib—CSF1R—cerebellum—peripheral nervous system neoplasm	0.000274	0.00584	CbGeAlD
Nilotinib—KIT—cerebellum—peripheral nervous system neoplasm	0.000249	0.00531	CbGeAlD
Nilotinib—PDGFRB—cerebellum—peripheral nervous system neoplasm	0.000243	0.00518	CbGeAlD
Nilotinib—ABL1—cerebellum—peripheral nervous system neoplasm	0.000217	0.00462	CbGeAlD
Nilotinib—ABL1—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000202	0.0454	CbGdCrCtD
Nilotinib—ABL1—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000202	0.0454	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000202	0.0454	CbGdCrCtD
Nilotinib—CYP2D6—brainstem—peripheral nervous system neoplasm	0.00019	0.00405	CbGeAlD
Nilotinib—ABL1—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.000187	0.042	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.000187	0.042	CbGdCrCtD
Nilotinib—ABL1—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000187	0.042	CbGdCrCtD
Nilotinib—CA4—cerebellum—peripheral nervous system neoplasm	0.000178	0.00379	CbGeAlD
Nilotinib—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000155	0.00329	CbGeAlD
Nilotinib—CA2—cerebellum—peripheral nervous system neoplasm	0.000148	0.00314	CbGeAlD
Nilotinib—ABCG2—cerebellum—peripheral nervous system neoplasm	0.000137	0.00291	CbGeAlD
Nilotinib—CYP2D6—cerebellum—peripheral nervous system neoplasm	9.38e-05	0.002	CbGeAlD
Nilotinib—ABCB1—cerebellum—peripheral nervous system neoplasm	6.75e-05	0.00144	CbGeAlD
Nilotinib—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	6.27e-05	0.000255	CcSEcCtD
Nilotinib—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	6.27e-05	0.000255	CcSEcCtD
Nilotinib—Asthenia—Vincristine—peripheral nervous system neoplasm	6.25e-05	0.000254	CcSEcCtD
Nilotinib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	6.24e-05	0.000254	CcSEcCtD
Nilotinib—Infestation—Epirubicin—peripheral nervous system neoplasm	6.2e-05	0.000252	CcSEcCtD
Nilotinib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	6.2e-05	0.000252	CcSEcCtD
Nilotinib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	6.2e-05	0.000252	CcSEcCtD
Nilotinib—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	6.19e-05	0.000252	CcSEcCtD
Nilotinib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	6.18e-05	0.000252	CcSEcCtD
Nilotinib—Rash—Dactinomycin—peripheral nervous system neoplasm	6.15e-05	0.00025	CcSEcCtD
Nilotinib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	6.13e-05	0.000249	CcSEcCtD
Nilotinib—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	6.11e-05	0.000249	CcSEcCtD
Nilotinib—Renal failure—Epirubicin—peripheral nervous system neoplasm	6.09e-05	0.000248	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	6.09e-05	0.000248	CcSEcCtD
Nilotinib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	6.09e-05	0.000248	CcSEcCtD
Nilotinib—Fatigue—Etoposide—peripheral nervous system neoplasm	6.08e-05	0.000247	CcSEcCtD
Nilotinib—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	6.08e-05	0.000247	CcSEcCtD
Nilotinib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	6.04e-05	0.000246	CcSEcCtD
Nilotinib—Jaundice—Epirubicin—peripheral nervous system neoplasm	6.04e-05	0.000246	CcSEcCtD
Nilotinib—Constipation—Etoposide—peripheral nervous system neoplasm	6.03e-05	0.000245	CcSEcCtD
Nilotinib—Pain—Etoposide—peripheral nervous system neoplasm	6.03e-05	0.000245	CcSEcCtD
Nilotinib—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	6.03e-05	0.000245	CcSEcCtD
Nilotinib—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	6.03e-05	0.000245	CcSEcCtD
Nilotinib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	6.02e-05	0.000245	CcSEcCtD
Nilotinib—Dysuria—Doxorubicin—peripheral nervous system neoplasm	6.02e-05	0.000245	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	5.98e-05	0.000243	CcSEcCtD
Nilotinib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	5.98e-05	0.000243	CcSEcCtD
Nilotinib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	5.96e-05	0.000242	CcSEcCtD
Nilotinib—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	5.94e-05	0.000242	CcSEcCtD
Nilotinib—Haematuria—Epirubicin—peripheral nervous system neoplasm	5.91e-05	0.00024	CcSEcCtD
Nilotinib—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	5.87e-05	0.000239	CcSEcCtD
Nilotinib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	5.86e-05	0.000239	CcSEcCtD
Nilotinib—Weight increased—Doxorubicin—peripheral nervous system neoplasm	5.86e-05	0.000238	CcSEcCtD
Nilotinib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	5.85e-05	0.000238	CcSEcCtD
Nilotinib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	5.82e-05	0.000237	CcSEcCtD
Nilotinib—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	5.81e-05	0.000236	CcSEcCtD
Nilotinib—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	5.8e-05	0.000236	CcSEcCtD
Nilotinib—Nausea—Dactinomycin—peripheral nervous system neoplasm	5.79e-05	0.000236	CcSEcCtD
Nilotinib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	5.77e-05	0.000235	CcSEcCtD
Nilotinib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	5.77e-05	0.000235	CcSEcCtD
Nilotinib—Dizziness—Vincristine—peripheral nervous system neoplasm	5.76e-05	0.000234	CcSEcCtD
Nilotinib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	5.75e-05	0.000234	CcSEcCtD
Nilotinib—Infestation—Doxorubicin—peripheral nervous system neoplasm	5.74e-05	0.000233	CcSEcCtD
Nilotinib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	5.74e-05	0.000233	CcSEcCtD
Nilotinib—Rash—Alitretinoin—peripheral nervous system neoplasm	5.7e-05	0.000232	CcSEcCtD
Nilotinib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	5.69e-05	0.000232	CcSEcCtD
Nilotinib—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	5.67e-05	0.000231	CcSEcCtD
Nilotinib—Bradycardia—Epirubicin—peripheral nervous system neoplasm	5.67e-05	0.00023	CcSEcCtD
Nilotinib—Headache—Alitretinoin—peripheral nervous system neoplasm	5.66e-05	0.00023	CcSEcCtD
Nilotinib—Renal failure—Doxorubicin—peripheral nervous system neoplasm	5.64e-05	0.000229	CcSEcCtD
Nilotinib—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	5.62e-05	0.000229	CcSEcCtD
Nilotinib—Urticaria—Etoposide—peripheral nervous system neoplasm	5.6e-05	0.000228	CcSEcCtD
Nilotinib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	5.59e-05	0.000228	CcSEcCtD
Nilotinib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	5.59e-05	0.000227	CcSEcCtD
Nilotinib—Jaundice—Doxorubicin—peripheral nervous system neoplasm	5.59e-05	0.000227	CcSEcCtD
Nilotinib—Rhinitis—Epirubicin—peripheral nervous system neoplasm	5.58e-05	0.000227	CcSEcCtD
Nilotinib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	5.58e-05	0.000227	CcSEcCtD
Nilotinib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	5.58e-05	0.000227	CcSEcCtD
Nilotinib—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	5.58e-05	0.000227	CcSEcCtD
Nilotinib—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	5.58e-05	0.000227	CcSEcCtD
Nilotinib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	5.57e-05	0.000226	CcSEcCtD
Nilotinib—Hepatitis—Epirubicin—peripheral nervous system neoplasm	5.57e-05	0.000226	CcSEcCtD
Nilotinib—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	5.54e-05	0.000225	CcSEcCtD
Nilotinib—Vomiting—Vincristine—peripheral nervous system neoplasm	5.54e-05	0.000225	CcSEcCtD
Nilotinib—Asthenia—Cisplatin—peripheral nervous system neoplasm	5.52e-05	0.000225	CcSEcCtD
Nilotinib—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	5.52e-05	0.000225	CcSEcCtD
Nilotinib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	5.5e-05	0.000224	CcSEcCtD
Nilotinib—Rash—Vincristine—peripheral nervous system neoplasm	5.49e-05	0.000223	CcSEcCtD
Nilotinib—Dermatitis—Vincristine—peripheral nervous system neoplasm	5.49e-05	0.000223	CcSEcCtD
Nilotinib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	5.48e-05	0.000223	CcSEcCtD
Nilotinib—Haematuria—Doxorubicin—peripheral nervous system neoplasm	5.47e-05	0.000223	CcSEcCtD
Nilotinib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	5.47e-05	0.000222	CcSEcCtD
Nilotinib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	5.46e-05	0.000222	CcSEcCtD
Nilotinib—Headache—Vincristine—peripheral nervous system neoplasm	5.46e-05	0.000222	CcSEcCtD
Nilotinib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	5.43e-05	0.000221	CcSEcCtD
Nilotinib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	5.41e-05	0.00022	CcSEcCtD
Nilotinib—Nausea—Alitretinoin—peripheral nervous system neoplasm	5.37e-05	0.000218	CcSEcCtD
Nilotinib—Visual impairment—Epirubicin—peripheral nervous system neoplasm	5.36e-05	0.000218	CcSEcCtD
Nilotinib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	5.27e-05	0.000214	CcSEcCtD
Nilotinib—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	5.26e-05	0.000214	CcSEcCtD
Nilotinib—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	5.24e-05	0.000213	CcSEcCtD
Nilotinib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	5.2e-05	0.000212	CcSEcCtD
Nilotinib—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	5.2e-05	0.000211	CcSEcCtD
Nilotinib—Tinnitus—Epirubicin—peripheral nervous system neoplasm	5.19e-05	0.000211	CcSEcCtD
Nilotinib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	5.18e-05	0.000211	CcSEcCtD
Nilotinib—Nausea—Vincristine—peripheral nervous system neoplasm	5.17e-05	0.00021	CcSEcCtD
Nilotinib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	5.17e-05	0.00021	CcSEcCtD
Nilotinib—Flushing—Epirubicin—peripheral nervous system neoplasm	5.17e-05	0.00021	CcSEcCtD
Nilotinib—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	5.16e-05	0.00021	CcSEcCtD
Nilotinib—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	5.15e-05	0.000209	CcSEcCtD
Nilotinib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	5.15e-05	0.000209	CcSEcCtD
Nilotinib—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	5.12e-05	0.000208	CcSEcCtD
Nilotinib—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	5.11e-05	0.000208	CcSEcCtD
Nilotinib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	5.09e-05	0.000207	CcSEcCtD
Nilotinib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	5.07e-05	0.000206	CcSEcCtD
Nilotinib—Asthenia—Etoposide—peripheral nervous system neoplasm	5.06e-05	0.000206	CcSEcCtD
Nilotinib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	5.06e-05	0.000206	CcSEcCtD
Nilotinib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	5.05e-05	0.000205	CcSEcCtD
Nilotinib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	5.05e-05	0.000205	CcSEcCtD
Nilotinib—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	5.03e-05	0.000205	CcSEcCtD
Nilotinib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	5.02e-05	0.000204	CcSEcCtD
Nilotinib—Chills—Epirubicin—peripheral nervous system neoplasm	4.99e-05	0.000203	CcSEcCtD
Nilotinib—Pruritus—Etoposide—peripheral nervous system neoplasm	4.99e-05	0.000203	CcSEcCtD
Nilotinib—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	4.97e-05	0.000202	CcSEcCtD
Nilotinib—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	4.96e-05	0.000202	CcSEcCtD
Nilotinib—Alopecia—Epirubicin—peripheral nervous system neoplasm	4.92e-05	0.0002	CcSEcCtD
Nilotinib—Vomiting—Cisplatin—peripheral nervous system neoplasm	4.9e-05	0.000199	CcSEcCtD
Nilotinib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	4.88e-05	0.000198	CcSEcCtD
Nilotinib—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	4.87e-05	0.000198	CcSEcCtD
Nilotinib—Rash—Cisplatin—peripheral nervous system neoplasm	4.86e-05	0.000198	CcSEcCtD
Nilotinib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	4.85e-05	0.000197	CcSEcCtD
Nilotinib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	4.85e-05	0.000197	CcSEcCtD
Nilotinib—Erythema—Epirubicin—peripheral nervous system neoplasm	4.85e-05	0.000197	CcSEcCtD
Nilotinib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	4.83e-05	0.000196	CcSEcCtD
Nilotinib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	4.81e-05	0.000196	CcSEcCtD
Nilotinib—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	4.8e-05	0.000195	CcSEcCtD
Nilotinib—Flushing—Doxorubicin—peripheral nervous system neoplasm	4.78e-05	0.000194	CcSEcCtD
Nilotinib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	4.78e-05	0.000194	CcSEcCtD
Nilotinib—Flatulence—Epirubicin—peripheral nervous system neoplasm	4.77e-05	0.000194	CcSEcCtD
Nilotinib—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	4.74e-05	0.000193	CcSEcCtD
Nilotinib—Back pain—Epirubicin—peripheral nervous system neoplasm	4.69e-05	0.000191	CcSEcCtD
Nilotinib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	4.67e-05	0.00019	CcSEcCtD
Nilotinib—Dizziness—Etoposide—peripheral nervous system neoplasm	4.66e-05	0.00019	CcSEcCtD
Nilotinib—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	4.66e-05	0.000189	CcSEcCtD
Nilotinib—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	4.65e-05	0.000189	CcSEcCtD
Nilotinib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	4.64e-05	0.000189	CcSEcCtD
Nilotinib—Chills—Doxorubicin—peripheral nervous system neoplasm	4.62e-05	0.000188	CcSEcCtD
Nilotinib—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	4.6e-05	0.000187	CcSEcCtD
Nilotinib—Nausea—Cisplatin—peripheral nervous system neoplasm	4.57e-05	0.000186	CcSEcCtD
Nilotinib—Vision blurred—Epirubicin—peripheral nervous system neoplasm	4.57e-05	0.000186	CcSEcCtD
Nilotinib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	4.55e-05	0.000185	CcSEcCtD
Nilotinib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	4.51e-05	0.000184	CcSEcCtD
Nilotinib—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	4.5e-05	0.000183	CcSEcCtD
Nilotinib—Vomiting—Etoposide—peripheral nervous system neoplasm	4.49e-05	0.000182	CcSEcCtD
Nilotinib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	4.48e-05	0.000182	CcSEcCtD
Nilotinib—Erythema—Doxorubicin—peripheral nervous system neoplasm	4.48e-05	0.000182	CcSEcCtD
Nilotinib—Anaemia—Epirubicin—peripheral nervous system neoplasm	4.48e-05	0.000182	CcSEcCtD
Nilotinib—Rash—Etoposide—peripheral nervous system neoplasm	4.45e-05	0.000181	CcSEcCtD
Nilotinib—Dermatitis—Etoposide—peripheral nervous system neoplasm	4.44e-05	0.000181	CcSEcCtD
Nilotinib—Headache—Etoposide—peripheral nervous system neoplasm	4.42e-05	0.00018	CcSEcCtD
Nilotinib—Flatulence—Doxorubicin—peripheral nervous system neoplasm	4.42e-05	0.00018	CcSEcCtD
Nilotinib—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	4.39e-05	0.000179	CcSEcCtD
Nilotinib—Malaise—Epirubicin—peripheral nervous system neoplasm	4.37e-05	0.000178	CcSEcCtD
Nilotinib—Vertigo—Epirubicin—peripheral nervous system neoplasm	4.35e-05	0.000177	CcSEcCtD
Nilotinib—Syncope—Epirubicin—peripheral nervous system neoplasm	4.34e-05	0.000177	CcSEcCtD
Nilotinib—Leukopenia—Epirubicin—peripheral nervous system neoplasm	4.34e-05	0.000176	CcSEcCtD
Nilotinib—Back pain—Doxorubicin—peripheral nervous system neoplasm	4.34e-05	0.000176	CcSEcCtD
Nilotinib—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	4.31e-05	0.000175	CcSEcCtD
Nilotinib—Palpitations—Epirubicin—peripheral nervous system neoplasm	4.28e-05	0.000174	CcSEcCtD
Nilotinib—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	4.26e-05	0.000173	CcSEcCtD
Nilotinib—Cough—Epirubicin—peripheral nervous system neoplasm	4.23e-05	0.000172	CcSEcCtD
Nilotinib—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	4.22e-05	0.000172	CcSEcCtD
Nilotinib—Nausea—Etoposide—peripheral nervous system neoplasm	4.19e-05	0.00017	CcSEcCtD
Nilotinib—Hypertension—Epirubicin—peripheral nervous system neoplasm	4.18e-05	0.00017	CcSEcCtD
Nilotinib—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	4.16e-05	0.000169	CcSEcCtD
Nilotinib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	4.14e-05	0.000169	CcSEcCtD
Nilotinib—Chest pain—Epirubicin—peripheral nervous system neoplasm	4.12e-05	0.000168	CcSEcCtD
Nilotinib—Myalgia—Epirubicin—peripheral nervous system neoplasm	4.12e-05	0.000168	CcSEcCtD
Nilotinib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	4.12e-05	0.000168	CcSEcCtD
Nilotinib—Anxiety—Epirubicin—peripheral nervous system neoplasm	4.11e-05	0.000167	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	4.1e-05	0.000167	CcSEcCtD
Nilotinib—Discomfort—Epirubicin—peripheral nervous system neoplasm	4.08e-05	0.000166	CcSEcCtD
Nilotinib—Malaise—Doxorubicin—peripheral nervous system neoplasm	4.04e-05	0.000164	CcSEcCtD
Nilotinib—Dry mouth—Epirubicin—peripheral nervous system neoplasm	4.03e-05	0.000164	CcSEcCtD
Nilotinib—Vertigo—Doxorubicin—peripheral nervous system neoplasm	4.03e-05	0.000164	CcSEcCtD
Nilotinib—Syncope—Doxorubicin—peripheral nervous system neoplasm	4.02e-05	0.000164	CcSEcCtD
Nilotinib—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	4.01e-05	0.000163	CcSEcCtD
Nilotinib—Confusional state—Epirubicin—peripheral nervous system neoplasm	3.99e-05	0.000162	CcSEcCtD
Nilotinib—Palpitations—Doxorubicin—peripheral nervous system neoplasm	3.96e-05	0.000161	CcSEcCtD
Nilotinib—Oedema—Epirubicin—peripheral nervous system neoplasm	3.95e-05	0.000161	CcSEcCtD
Nilotinib—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	3.94e-05	0.00016	CcSEcCtD
Nilotinib—Infection—Epirubicin—peripheral nervous system neoplasm	3.93e-05	0.00016	CcSEcCtD
Nilotinib—Cough—Doxorubicin—peripheral nervous system neoplasm	3.91e-05	0.000159	CcSEcCtD
Nilotinib—Shock—Epirubicin—peripheral nervous system neoplasm	3.89e-05	0.000158	CcSEcCtD
Nilotinib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	3.88e-05	0.000158	CcSEcCtD
Nilotinib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	3.87e-05	0.000157	CcSEcCtD
Nilotinib—Hypertension—Doxorubicin—peripheral nervous system neoplasm	3.87e-05	0.000157	CcSEcCtD
Nilotinib—Tachycardia—Epirubicin—peripheral nervous system neoplasm	3.86e-05	0.000157	CcSEcCtD
Nilotinib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	3.84e-05	0.000156	CcSEcCtD
Nilotinib—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	3.82e-05	0.000156	CcSEcCtD
Nilotinib—Chest pain—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.000155	CcSEcCtD
Nilotinib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.000155	CcSEcCtD
Nilotinib—Myalgia—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.000155	CcSEcCtD
Nilotinib—Anxiety—Doxorubicin—peripheral nervous system neoplasm	3.8e-05	0.000155	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	3.79e-05	0.000154	CcSEcCtD
Nilotinib—Discomfort—Doxorubicin—peripheral nervous system neoplasm	3.77e-05	0.000153	CcSEcCtD
Nilotinib—Anorexia—Epirubicin—peripheral nervous system neoplasm	3.77e-05	0.000153	CcSEcCtD
Nilotinib—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	3.73e-05	0.000152	CcSEcCtD
Nilotinib—Hypotension—Epirubicin—peripheral nervous system neoplasm	3.69e-05	0.00015	CcSEcCtD
Nilotinib—Confusional state—Doxorubicin—peripheral nervous system neoplasm	3.69e-05	0.00015	CcSEcCtD
Nilotinib—Oedema—Doxorubicin—peripheral nervous system neoplasm	3.66e-05	0.000149	CcSEcCtD
Nilotinib—Infection—Doxorubicin—peripheral nervous system neoplasm	3.63e-05	0.000148	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	3.6e-05	0.000147	CcSEcCtD
Nilotinib—Shock—Doxorubicin—peripheral nervous system neoplasm	3.6e-05	0.000146	CcSEcCtD
Nilotinib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	3.59e-05	0.000146	CcSEcCtD
Nilotinib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	3.58e-05	0.000146	CcSEcCtD
Nilotinib—Insomnia—Epirubicin—peripheral nervous system neoplasm	3.58e-05	0.000145	CcSEcCtD
Nilotinib—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	3.57e-05	0.000145	CcSEcCtD
Nilotinib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	3.55e-05	0.000145	CcSEcCtD
Nilotinib—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	3.55e-05	0.000144	CcSEcCtD
Nilotinib—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	3.54e-05	0.000144	CcSEcCtD
Nilotinib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	3.53e-05	0.000143	CcSEcCtD
Nilotinib—Anorexia—Doxorubicin—peripheral nervous system neoplasm	3.49e-05	0.000142	CcSEcCtD
Nilotinib—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	3.48e-05	0.000142	CcSEcCtD
Nilotinib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	3.44e-05	0.00014	CcSEcCtD
Nilotinib—Hypotension—Doxorubicin—peripheral nervous system neoplasm	3.42e-05	0.000139	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	3.41e-05	0.000139	CcSEcCtD
Nilotinib—Fatigue—Epirubicin—peripheral nervous system neoplasm	3.41e-05	0.000139	CcSEcCtD
Nilotinib—Pain—Epirubicin—peripheral nervous system neoplasm	3.38e-05	0.000138	CcSEcCtD
Nilotinib—Constipation—Epirubicin—peripheral nervous system neoplasm	3.38e-05	0.000138	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	3.33e-05	0.000136	CcSEcCtD
Nilotinib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	3.31e-05	0.000135	CcSEcCtD
Nilotinib—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	3.29e-05	0.000134	CcSEcCtD
Nilotinib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	3.26e-05	0.000133	CcSEcCtD
Nilotinib—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	3.26e-05	0.000133	CcSEcCtD
Nilotinib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	3.23e-05	0.000132	CcSEcCtD
Nilotinib—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	3.22e-05	0.000131	CcSEcCtD
Nilotinib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	3.18e-05	0.000129	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.16e-05	0.000128	CcSEcCtD
Nilotinib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	3.15e-05	0.000128	CcSEcCtD
Nilotinib—Urticaria—Epirubicin—peripheral nervous system neoplasm	3.14e-05	0.000128	CcSEcCtD
Nilotinib—Pain—Doxorubicin—peripheral nervous system neoplasm	3.13e-05	0.000127	CcSEcCtD
Nilotinib—Constipation—Doxorubicin—peripheral nervous system neoplasm	3.13e-05	0.000127	CcSEcCtD
Nilotinib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	3.13e-05	0.000127	CcSEcCtD
Nilotinib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	3.13e-05	0.000127	CcSEcCtD
Nilotinib—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	3.02e-05	0.000123	CcSEcCtD
Nilotinib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	2.99e-05	0.000122	CcSEcCtD
Nilotinib—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	2.91e-05	0.000119	CcSEcCtD
Nilotinib—Urticaria—Doxorubicin—peripheral nervous system neoplasm	2.91e-05	0.000118	CcSEcCtD
Nilotinib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	2.89e-05	0.000118	CcSEcCtD
Nilotinib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	2.89e-05	0.000118	CcSEcCtD
Nilotinib—Asthenia—Epirubicin—peripheral nervous system neoplasm	2.84e-05	0.000115	CcSEcCtD
Nilotinib—Pruritus—Epirubicin—peripheral nervous system neoplasm	2.8e-05	0.000114	CcSEcCtD
Nilotinib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	2.71e-05	0.00011	CcSEcCtD
Nilotinib—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	2.7e-05	0.00011	CcSEcCtD
Nilotinib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	2.63e-05	0.000107	CcSEcCtD
Nilotinib—Dizziness—Epirubicin—peripheral nervous system neoplasm	2.61e-05	0.000106	CcSEcCtD
Nilotinib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	2.59e-05	0.000105	CcSEcCtD
Nilotinib—Vomiting—Epirubicin—peripheral nervous system neoplasm	2.51e-05	0.000102	CcSEcCtD
Nilotinib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	2.5e-05	0.000102	CcSEcCtD
Nilotinib—Rash—Epirubicin—peripheral nervous system neoplasm	2.49e-05	0.000101	CcSEcCtD
Nilotinib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	2.49e-05	0.000101	CcSEcCtD
Nilotinib—Headache—Epirubicin—peripheral nervous system neoplasm	2.48e-05	0.000101	CcSEcCtD
Nilotinib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	2.42e-05	9.84e-05	CcSEcCtD
Nilotinib—Nausea—Epirubicin—peripheral nervous system neoplasm	2.35e-05	9.55e-05	CcSEcCtD
Nilotinib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	2.33e-05	9.46e-05	CcSEcCtD
Nilotinib—Rash—Doxorubicin—peripheral nervous system neoplasm	2.31e-05	9.38e-05	CcSEcCtD
Nilotinib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.3e-05	9.38e-05	CcSEcCtD
Nilotinib—Headache—Doxorubicin—peripheral nervous system neoplasm	2.29e-05	9.32e-05	CcSEcCtD
Nilotinib—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.17e-05	8.84e-05	CcSEcCtD
Nilotinib—MAPK14—Signaling Pathways—GNAS—peripheral nervous system neoplasm	6.88e-06	3.83e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—peripheral nervous system neoplasm	6.85e-06	3.81e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—ERBB2—peripheral nervous system neoplasm	6.82e-06	3.8e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—peripheral nervous system neoplasm	6.82e-06	3.8e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KNG1—peripheral nervous system neoplasm	6.81e-06	3.79e-05	CbGpPWpGaD
Nilotinib—CA14—Metabolism—AKT1—peripheral nervous system neoplasm	6.78e-06	3.78e-05	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	6.78e-06	3.78e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	6.77e-06	3.77e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.7e-06	3.73e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—HRAS—peripheral nervous system neoplasm	6.68e-06	3.72e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—HRAS—peripheral nervous system neoplasm	6.68e-06	3.72e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.65e-06	3.7e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—HRAS—peripheral nervous system neoplasm	6.64e-06	3.7e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.64e-06	3.7e-05	CbGpPWpGaD
Nilotinib—CA6—Metabolism—AKT1—peripheral nervous system neoplasm	6.61e-06	3.68e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—NRAS—peripheral nervous system neoplasm	6.61e-06	3.68e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	6.6e-06	3.67e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—BCHE—peripheral nervous system neoplasm	6.59e-06	3.67e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—HRAS—peripheral nervous system neoplasm	6.55e-06	3.65e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—HRAS—peripheral nervous system neoplasm	6.52e-06	3.63e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—peripheral nervous system neoplasm	6.49e-06	3.61e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	6.49e-06	3.61e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—ERBB2—peripheral nervous system neoplasm	6.46e-06	3.6e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	6.42e-06	3.57e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	6.41e-06	3.57e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—PTPN11—peripheral nervous system neoplasm	6.4e-06	3.56e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	6.34e-06	3.53e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—HRAS—peripheral nervous system neoplasm	6.33e-06	3.52e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.32e-06	3.52e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—HRAS—peripheral nervous system neoplasm	6.32e-06	3.52e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—ERBB2—peripheral nervous system neoplasm	6.3e-06	3.51e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.28e-06	3.5e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—AKT1—peripheral nervous system neoplasm	6.23e-06	3.47e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—NRAS—peripheral nervous system neoplasm	6.23e-06	3.47e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—HRAS—peripheral nervous system neoplasm	6.21e-06	3.46e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—TH—peripheral nervous system neoplasm	6.19e-06	3.45e-05	CbGpPWpGaD
Nilotinib—CA7—Metabolism—AKT1—peripheral nervous system neoplasm	6.17e-06	3.44e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—ERBB2—peripheral nervous system neoplasm	6.17e-06	3.44e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—ERBB2—peripheral nervous system neoplasm	6.14e-06	3.42e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.04e-06	3.37e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.04e-06	3.36e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—HRAS—peripheral nervous system neoplasm	6.02e-06	3.35e-05	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.99e-06	3.33e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.95e-06	3.31e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTPN11—peripheral nervous system neoplasm	5.91e-06	3.29e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.9e-06	3.29e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.9e-06	3.28e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—AKT1—peripheral nervous system neoplasm	5.89e-06	3.28e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.87e-06	3.27e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—AKT1—peripheral nervous system neoplasm	5.87e-06	3.27e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—ERBB2—peripheral nervous system neoplasm	5.85e-06	3.26e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	5.85e-06	3.26e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—HRAS—peripheral nervous system neoplasm	5.83e-06	3.25e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—ERBB2—peripheral nervous system neoplasm	5.82e-06	3.24e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	5.78e-06	3.22e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—AKT1—peripheral nervous system neoplasm	5.78e-06	3.22e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—MYC—peripheral nervous system neoplasm	5.77e-06	3.22e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—AKT1—peripheral nervous system neoplasm	5.76e-06	3.2e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	5.75e-06	3.2e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.74e-06	3.2e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—HRAS—peripheral nervous system neoplasm	5.72e-06	3.19e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—HRAS—peripheral nervous system neoplasm	5.72e-06	3.19e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.72e-06	3.19e-05	CbGpPWpGaD
Nilotinib—CA12—Metabolism—AKT1—peripheral nervous system neoplasm	5.72e-06	3.18e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—HRAS—peripheral nervous system neoplasm	5.71e-06	3.18e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—NRAS—peripheral nervous system neoplasm	5.7e-06	3.18e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.67e-06	3.16e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	5.66e-06	3.15e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—NRAS—peripheral nervous system neoplasm	5.62e-06	3.13e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—peripheral nervous system neoplasm	5.61e-06	3.13e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	5.61e-06	3.12e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.59e-06	3.11e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—AKT1—peripheral nervous system neoplasm	5.59e-06	3.11e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—AKT1—peripheral nervous system neoplasm	5.58e-06	3.11e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	5.58e-06	3.11e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—AKT1—peripheral nervous system neoplasm	5.48e-06	3.05e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	5.42e-06	3.02e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	5.41e-06	3.01e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	5.4e-06	3e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	5.37e-06	2.99e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—HRAS—peripheral nervous system neoplasm	5.37e-06	2.99e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—NRAS—peripheral nervous system neoplasm	5.32e-06	2.96e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.32e-06	2.96e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.32e-06	2.96e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—MYC—peripheral nervous system neoplasm	5.31e-06	2.96e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.3e-06	2.95e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.25e-06	2.92e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	5.24e-06	2.92e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.21e-06	2.9e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—NRAS—peripheral nervous system neoplasm	5.19e-06	2.89e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.18e-06	2.89e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.15e-06	2.87e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—AKT1—peripheral nervous system neoplasm	5.15e-06	2.87e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.11e-06	2.84e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.06e-06	2.82e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—ERBB2—peripheral nervous system neoplasm	5.06e-06	2.82e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GNAS—peripheral nervous system neoplasm	5.06e-06	2.82e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—AKT1—peripheral nervous system neoplasm	5.05e-06	2.81e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—AKT1—peripheral nervous system neoplasm	5.05e-06	2.81e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.05e-06	2.81e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—AKT1—peripheral nervous system neoplasm	5.04e-06	2.81e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5e-06	2.78e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ABCB1—peripheral nervous system neoplasm	4.96e-06	2.76e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—AKT1—peripheral nervous system neoplasm	4.93e-06	2.75e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—NRAS—peripheral nervous system neoplasm	4.91e-06	2.74e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	4.86e-06	2.71e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—MYC—peripheral nervous system neoplasm	4.83e-06	2.69e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—HRAS—peripheral nervous system neoplasm	4.83e-06	2.69e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.81e-06	2.68e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.81e-06	2.68e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—NRAS—peripheral nervous system neoplasm	4.79e-06	2.67e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.78e-06	2.66e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.78e-06	2.66e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.76e-06	2.65e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—AKT1—peripheral nervous system neoplasm	4.74e-06	2.64e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.71e-06	2.62e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—NRAS—peripheral nervous system neoplasm	4.69e-06	2.61e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—NRAS—peripheral nervous system neoplasm	4.67e-06	2.6e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—ERBB2—peripheral nervous system neoplasm	4.67e-06	2.6e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	4.64e-06	2.58e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.63e-06	2.58e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	4.58e-06	2.55e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MYC—peripheral nervous system neoplasm	4.58e-06	2.55e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	4.57e-06	2.54e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HRAS—peripheral nervous system neoplasm	4.56e-06	2.54e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—AKT1—peripheral nervous system neoplasm	4.56e-06	2.54e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	4.54e-06	2.53e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.52e-06	2.52e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.48e-06	2.49e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NRAS—peripheral nervous system neoplasm	4.45e-06	2.48e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NRAS—peripheral nervous system neoplasm	4.43e-06	2.46e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—AKT1—peripheral nervous system neoplasm	4.37e-06	2.43e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.37e-06	2.43e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.34e-06	2.41e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.33e-06	2.41e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	4.3e-06	2.4e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	4.28e-06	2.38e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	4.27e-06	2.38e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—AKT1—peripheral nervous system neoplasm	4.27e-06	2.38e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	4.2e-06	2.34e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AKT1—peripheral nervous system neoplasm	4.19e-06	2.33e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—HRAS—peripheral nervous system neoplasm	4.17e-06	2.32e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.14e-06	2.3e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MYC—peripheral nervous system neoplasm	4.12e-06	2.3e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—MYC—peripheral nervous system neoplasm	4.12e-06	2.3e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—HRAS—peripheral nervous system neoplasm	4.11e-06	2.29e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.1e-06	2.29e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	4.1e-06	2.28e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.07e-06	2.27e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.03e-06	2.24e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—AKT1—peripheral nervous system neoplasm	4.03e-06	2.24e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—AKT1—peripheral nervous system neoplasm	4e-06	2.23e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.99e-06	2.22e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.99e-06	2.22e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HRAS—peripheral nervous system neoplasm	3.89e-06	2.17e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.87e-06	2.15e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—NRAS—peripheral nervous system neoplasm	3.85e-06	2.14e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—HRAS—peripheral nervous system neoplasm	3.8e-06	2.11e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.78e-06	2.11e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.75e-06	2.09e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	3.73e-06	2.08e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.72e-06	2.07e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.7e-06	2.06e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.7e-06	2.06e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—peripheral nervous system neoplasm	3.68e-06	2.05e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—peripheral nervous system neoplasm	3.68e-06	2.05e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.68e-06	2.05e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.63e-06	2.02e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—peripheral nervous system neoplasm	3.63e-06	2.02e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.62e-06	2.02e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HRAS—peripheral nervous system neoplasm	3.59e-06	2e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NRAS—peripheral nervous system neoplasm	3.55e-06	1.98e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	3.54e-06	1.97e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.52e-06	1.96e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	3.51e-06	1.96e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—peripheral nervous system neoplasm	3.51e-06	1.95e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	3.48e-06	1.94e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	3.45e-06	1.92e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.44e-06	1.92e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—peripheral nervous system neoplasm	3.44e-06	1.91e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—peripheral nervous system neoplasm	3.43e-06	1.91e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.43e-06	1.91e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	3.42e-06	1.9e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—peripheral nervous system neoplasm	3.42e-06	1.9e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.39e-06	1.89e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—peripheral nervous system neoplasm	3.35e-06	1.87e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—peripheral nervous system neoplasm	3.31e-06	1.84e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.27e-06	1.82e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.27e-06	1.82e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—peripheral nervous system neoplasm	3.26e-06	1.81e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—peripheral nervous system neoplasm	3.24e-06	1.8e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.2e-06	1.78e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—peripheral nervous system neoplasm	3.17e-06	1.77e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.11e-06	1.73e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.1e-06	1.73e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—peripheral nervous system neoplasm	3.1e-06	1.72e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.08e-06	1.72e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.05e-06	1.7e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.03e-06	1.69e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—peripheral nervous system neoplasm	3.03e-06	1.69e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—peripheral nervous system neoplasm	3.02e-06	1.68e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	2.99e-06	1.67e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.97e-06	1.65e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.95e-06	1.64e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.92e-06	1.63e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.89e-06	1.61e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.88e-06	1.6e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—peripheral nervous system neoplasm	2.87e-06	1.6e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—peripheral nervous system neoplasm	2.86e-06	1.59e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—peripheral nervous system neoplasm	2.86e-06	1.59e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.86e-06	1.59e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.83e-06	1.57e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—peripheral nervous system neoplasm	2.81e-06	1.57e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	2.81e-06	1.57e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.78e-06	1.55e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.68e-06	1.49e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.66e-06	1.48e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.63e-06	1.47e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.6e-06	1.45e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—peripheral nervous system neoplasm	2.6e-06	1.45e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.58e-06	1.44e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.52e-06	1.4e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.49e-06	1.39e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—peripheral nervous system neoplasm	2.49e-06	1.38e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.37e-06	1.32e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.35e-06	1.31e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.32e-06	1.29e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.32e-06	1.29e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	2.3e-06	1.28e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—peripheral nervous system neoplasm	2.29e-06	1.28e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.27e-06	1.26e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	2.25e-06	1.26e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.22e-06	1.24e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.22e-06	1.24e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.2e-06	1.23e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—peripheral nervous system neoplasm	2.19e-06	1.22e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.1e-06	1.17e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2e-06	1.11e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.96e-06	1.09e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.9e-06	1.06e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	1.86e-06	1.04e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.86e-06	1.03e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.82e-06	1.01e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.61e-06	8.95e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—peripheral nervous system neoplasm	1.36e-06	7.6e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	1.16e-06	6.43e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	1.01e-06	5.6e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	9.48e-07	5.28e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	9.4e-07	5.24e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	6.2e-07	3.45e-06	CbGpPWpGaD
